REPL Stockholders Have Rights – If You Lost Money Investing in Replimune Group, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Robbins LLP said it is investigating allegations that Replimune Group, Inc. misled investors about the efficacy and viability of its lead product candidate, RP1. The inquiry raises legal and credibility risk around the program’s prospects, which could weigh on sentiment for the stock despite no quantified financial impact disclosed in the article.